Aquestive Therapeutics Inc (AQST)
5.15
-0.37
(-6.70%)
USD |
NASDAQ |
Nov 04, 16:00
5.10
-0.05
(-0.97%)
After-Hours: 07:48
Aquestive Therapeutics Profit Margin (Quarterly): -13.66% for June 30, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -13.66% |
| March 31, 2024 | -106.4% |
| December 31, 2023 | -61.42% |
| September 30, 2023 | -15.65% |
| June 30, 2023 | -43.74% |
| March 31, 2023 | 72.46% |
| December 31, 2022 | -115.6% |
| September 30, 2022 | -109.4% |
| June 30, 2022 | -122.9% |
| March 31, 2022 | -107.7% |
| December 31, 2021 | -261.3% |
| September 30, 2021 | -109.5% |
| June 30, 2021 | -80.59% |
| March 31, 2021 | -131.9% |
| December 31, 2020 | -284.9% |
| Date | Value |
|---|---|
| September 30, 2020 | -200.4% |
| June 30, 2020 | -10.77% |
| March 31, 2020 | -188.6% |
| December 31, 2019 | -76.96% |
| September 30, 2019 | -148.3% |
| June 30, 2019 | -184.0% |
| March 31, 2019 | -116.5% |
| December 31, 2018 | -82.88% |
| September 30, 2018 | -113.3% |
| June 30, 2018 | -262.0% |
| March 31, 2018 | 17.51% |
| December 31, 2017 | -82.33% |
| September 30, 2017 | 31.13% |
| June 30, 2017 | -52.93% |
| March 31, 2017 | -8.86% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-284.9%
Minimum
Dec 2020
72.46%
Maximum
Mar 2023
-103.6%
Average
-107.7%
Median
Mar 2022
Profit Margin (Quarterly) Benchmarks
| ACADIA Pharmaceuticals Inc | 13.80% |
| Rockwell Medical Inc | 1.33% |
| Cormedix Inc | -24.24% |
| Geovax Labs Inc | -1.68K% |
| Myomo Inc | -14.91% |
Profit Margin (Quarterly) Related Metrics
| Return on Assets | -30.55% |
| Gross Profit Margin (Quarterly) | 77.48% |
| Operating Margin (Quarterly) | 0.27% |
| Return on Net Operating Assets | -98.68% |